Raymond James & Associates’s Veracyte VCYT Stock Holding History

Raymond James & Associates’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-82,230	Closed	-$1.64M	–	4148
2022 Q2	$1.64M	Buy	+82,230	New	+$1.66M	﹤0.01%	2121
2020 Q1	–	Sell	-11,816	Closed	-$330K	–	3724
2019 Q4	$330K	Sell	11,816 -7,458	-39%	-$193K	﹤0.01%	3024
2019 Q3	$463K	Buy	19,274 +3,647	+23%	+$97K	﹤0.01%	2703
2019 Q2	$446K	Buy	+15,627	New	+$390K	﹤0.01%	2761
2018 Q2	–	Sell	-25,000	Closed	-$139K	–	3677
2018 Q1	$139K	Buy	+25,000	New	+$155K	﹤0.01%	3224

Other funds holding VCYT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Raymond James & Associates's VCYT Position: Q3 2022 in Review

Raymond James & Associates sold out of Veracyte (VCYT) in Q3 2022, closing a stake of 82,230 shares — an estimated $1.64M sold.

Raymond James & Associates first reported a position in VCYT in Q1 2018 and held it in 5 quarters. The position peaked at $1.64M in Q2 2022. 208 funds tracked by Wall St. Rank hold VCYT as of Q3 2022.

Raymond James & Associates reported no remaining Veracyte position as of Q3 2022 after selling out during the quarter.
Raymond James & Associates sold 82,230 Veracyte shares in Q3 2022, an estimated $1.64M.
Raymond James & Associates first reported a position in Veracyte in Q1 2018 and held it in 5 quarters.
Raymond James & Associates's Veracyte position peaked at $1.64M in Q2 2022.
208 funds tracked by Wall St. Rank held Veracyte as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.